Altimmune, Inc. (ALT) Stock Price & How to Invest

Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo.

The company generates no product revenue and funds itself through cash raised in the capital markets. Management planned to advance pemvidutide into a multinational Phase 3 MASH trial (PERFORMA) in the second half of 2026. As a single-asset, pre-commercial biotech, Altimmune's prospects hinge on clinical readouts, regulatory decisions, its cash runway, and whether it can differentiate in a GLP-1 obesity market dominated by much larger competitors.

Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders.

9 analysts publish price targets on ALT, averaging $17.22 against a $2.84 price as of August 2026, or +506.3%. The published targets run from $11.00 to $28.00, a wide spread, and the ratings split 9 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ALT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Altimmune, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Differentiated GLP-1/glucagon profile. Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. The most optimistic published target, $28.00, assumes this works close to its best case.

The case against. Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. The most pessimistic target, $11.00, is roughly what ALT is worth if this bites instead.

Read the full bull and bear case on ALT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Altimmune, Inc.'s investor relations page or your broker.

• Product revenue: None (clinical-stage)
• Cash + short-term investments: ~$535 million
• Lead program: Pemvidutide (obesity, MASH)
• MASH stage: Phase 3 (PERFORMA) planned H2 2026
• Valuation basis: Pipeline / clinical optionality

As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. The roughly $535 million cash position is a key strength because it funds expensive Phase 3 work, but the eventual value depends on trial outcomes and approval, both of which are uncertain.

Other names that sit close to ALT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ALT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ALT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Altimmune is a one-asset story: pemvidutide's data in MASH and obesity determines almost everything. If you believe its weight-loss-plus-liver profile can carve out a niche against far larger GLP-1 rivals, the question becomes how much binary clinical risk you want and how to size it, not timing. The risk is that a single failed trial or a financing crunch can erase much of the value, and the company competes against Novo Nordisk and Eli Lilly with a fraction of their resources.

Whether ALT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALT a buy or a sell?, and where the stock could go from here in the ALT stock forecast.

For income investors, whether ALT pays a dividend and how the payout looks is covered in does ALT pay a dividend? And to weigh ALT against a peer, read the full side-by-side comparisons: ALT vs NVO and ALT vs LLY.